Literature DB >> 10833943

[Computer-based morphometric image analysis of endometrial hyperplasia].

A Orbo1, J P Baak.   

Abstract

Former studies have shown that only 20% of endometrial hyperplasias progress to carcinoma. Objective criteria for predicting the outcome of hyperplasias have been lacking. Because hysterectomy has been the therapy of choice to avoid malignant development, overtreatment of these patients is still a clinical problem. A computer-based morphometric image analysis system has proved to be a considerable improvement for the pathologist in assessing which patients will develop cancer. The system is based on ten nuclear and twelve glandular architectural features. The three parameters with the best statistical power of discriminating between patients developing malignancy and those remaining healthy were combined into a morphometric classification rule (D-score or discriminating score). We give a brief description of this method and its background.

Entities:  

Mesh:

Year:  2000        PMID: 10833943

Source DB:  PubMed          Journal:  Tidsskr Nor Laegeforen        ISSN: 0029-2001


  3 in total

1.  Karyometry in atypical endometrial hyperplasia: a Gynecologic Oncology Group study.

Authors:  Peter H Bartels; Francisco A R Garcia; Cornelia L Trimble; James Kauderer; John Curtin; Peter C Lim; Lisa M Hess; Steven Silverberg; Richard J Zaino; Michael Yozwiak; Hubert G Bartels; David S Alberts
Journal:  Gynecol Oncol       Date:  2011-12-09       Impact factor: 5.482

2.  Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis.

Authors:  Jonathan L Hecht; Tan A Ince; Jan P A Baak; Heather E Baker; Maryann W Ogden; George L Mutter
Journal:  Mod Pathol       Date:  2005-03       Impact factor: 7.842

3.  Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial.

Authors:  A Orbo; Ab Vereide; M Arnes; I Pettersen; B Straume
Journal:  BJOG       Date:  2013-11-28       Impact factor: 6.531

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.